Last reviewed · How we verify
NaCl 7.5%
Hypertonic saline (7.5% NaCl) increases serum osmolality to draw fluid from intracellular and interstitial spaces into the intravascular compartment, reducing intracranial pressure and improving cellular hydration status.
Hypertonic saline (7.5% NaCl) increases serum osmolality to draw fluid from intracellular and interstitial spaces into the intravascular compartment, reducing intracranial pressure and improving cellular hydration status. Used for Elevated intracranial pressure / cerebral edema, Severe hyponatremia, Hypovolemic shock.
At a glance
| Generic name | NaCl 7.5% |
|---|---|
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Osmotic agent / Electrolyte solution |
| Modality | Small molecule |
| Therapeutic area | Neurology / Critical Care / Emergency Medicine |
| Phase | FDA-approved |
Mechanism of action
The high sodium chloride concentration creates an osmotic gradient that mobilizes fluid from tissues into the bloodstream, thereby reducing brain edema and intracranial hypertension. This is particularly useful in acute neurological emergencies where rapid reduction of cerebral edema is critical. The solution also restores electrolyte balance in severely hyponatremic or hypovolemic states.
Approved indications
- Elevated intracranial pressure / cerebral edema
- Severe hyponatremia
- Hypovolemic shock
Common side effects
- Hypernatremia
- Hyperchloremia
- Phlebitis (at infusion site)
- Rebound intracranial hypertension
Key clinical trials
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Does the Common Practice of Adding Diluted Epinephrine in Tranverse Abdominal Plan Block to Ropivacaine Significantly Decrease the Peak Systemic Resorption of Ropivacaine? (NA)
- Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis (PHASE3)
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults (PHASE1)
- Comparison of Lumbar Erector Spinae Plane Block and Spinal Anesthesia in Hip and Proximal Femur Surgery (NA)
- PRO-RSTAP: Effect of TAP and RS Blocks on Recovery After Inguinal Hernia Surgery (PRO-RSTAP) (NA)
- RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine) (PHASE2)
- Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaCl 7.5% CI brief — competitive landscape report
- NaCl 7.5% updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI